Description:
IMCnyeso is a new biological therapy designed for the treatment of cancers which express
NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and
efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and
whose cancer is positive for NY-ESO-1 and/or LAGE-A1.
Title
- Brief Title: Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
- Official Title: A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Clinical Trial IDs
- ORG STUDY ID:
IMCnyeso-101
- NCT ID:
NCT03515551
Conditions
- Melanoma
- Advanced NSCLC
- Urothelial Carcinoma
- Synovial Sarcoma
Interventions
Drug | Synonyms | Arms |
---|
IMCnyeso | | IMCnyeso dose Escalation Phase (Arm 1) |
IMCnyeso | | IMCnyeso expansion phase (Arm 2) |
Purpose
IMCnyeso is a new biological therapy designed for the treatment of cancers which express
NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and
efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and
whose cancer is positive for NY-ESO-1 and/or LAGE-A1.
Detailed Description
This is a multi-center, open label, dose finding Phase 1/2 study of single agent IMCnyeso
administered in patients with NY-ESO-1 and/or LAGE-A1 positive tumors. The study consists of
2 Arms. In the first Arm (the dose escalation phase), IMCnyeso will be evaluated in 4
diseases (advanced non-small cell cancer (NSCLC), melanoma, urothelial carcinoma, and
synovial sarcoma). The primary objective of this Arm is to determine the maximum tolerated
dose (MTD) and/or recommended Phase II dose (RP2D) of IMCnyeso. The second Arm is an
expansion phase in which the dose determined in Arm 1 will be tested in 3 diseases (advanced
NSCLC, urothelial carcinoma and synovial sarcoma) to further evaluate the safety and assess
the anti-tumor activity of IMCnyeso
Trial Arms
Name | Type | Description | Interventions |
---|
IMCnyeso dose Escalation Phase (Arm 1) | Experimental | Phase (Arm 1) n=up to 33 Melanoma, NSCLC, urothelial carcinoma and synovial sarcoma patients to establish the MTD/RP2D | |
IMCnyeso expansion phase (Arm 2) | Experimental | Patients will be enrolled into 1 of 3 cohorts depending on disease type (NSCLC, urothelial carcinoma or synovial sarcoma) n=30 and treated at the RP2D of IMCnyso to determine the efficacy in these indications | |
Eligibility Criteria
Inclusion Criteria:
1. Male or female patients age ≥ 18 years of age at the time of informed consent
2. HLA-A*0201 positive, confirmed by central laboratory
3. NY-ESO-1 and/or LAGE-1A positive tumor confirmed by the central laboratory
4. Arm 1: Patients must be refractory to or intolerant to all existing therapies known to
provide clinical benefit for their condition.
5. Arm 2: Subjects will have received the following previous therapies:
1. NSCLC — PD-1/PD-L1 inhibitor
2. Patients with NSCLC and an EGFR or ALK genomic tumor aberration must have disease
progression after treatment with Health Authority-approved agents for these
aberrations
3. Urothelial cancer — PD-1/PD-L1 inhibitor
4. Synovial sarcoma — at least one prior chemotherapy regimen
6. Arm 1 only: Histologically confirmed diagnosis of advanced NSCLC, melanoma, urothelial
carcinoma, or synovial sarcoma
7. Arm 2 only: Histologically confirmed diagnosis of advanced NSCLC, urothelial
carcinoma, or synovial sarcoma
8. Arm 2 only: Disease amenable to biopsy
9. Arm 2 only: Measurable disease to RECIST v.1.1 criteria
Exclusion Criteria:
Impaired baseline organ function as evaluated by out-of-range laboratory values 2. History
of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or
monoclonal antibodies 3. Clinically significant cardiac disease or impaired cardiac
function 4. Presence of symptomatic or untreated central nervous system (CNS) metastases 5.
Active infection requiring systemic antibiotic therapy 6. Known history of human
immunodeficiency virus infection (HIV) 7. Active hepatitis B virus (HBV) or hepatitis C
virus (HCV) infection 8. Malignant disease, other than that being treated in this study 9.
Patients receiving systemic steroid therapy or any other systemic immunosuppressive
medication. Local steroid therapies are acceptable 10. Systemic anti-cancer therapy within
2 weeks of the first dose of study drug.
11. Major surgery within 2 weeks of the first dose of study drug 12. Radiotherapy within 2
weeks of the first dose of study drug, with the exception of palliative radiotherapy to a
limited field 13. Use of hematopoietic colony-stimulating growth factors (eg, G-CSF,
GM-CSF, M-CSF) ≤ 2 weeks prior to start of study drug 14. Pregnant, likely to become
pregnant, or lactating women
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Recommended phase 2 dose (RP2D) |
Time Frame: | From day 1 to day 28 of treatment |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Objective response rate (ORR) defined as the proportion of patients achieving an objective response (RECIST v1.1 and modified irRECIST) (Arm 2 only) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Disease control rate (DCR) defined as the proportion of patients with either an objective response or stable disease (RECIST v1.1 and modified irRECIST). (Part 2 only) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Pharmacokinetics |
Time Frame: | 2 weeks (AUC will be assessed weekly for 2 weeks) |
Safety Issue: | |
Description: | Area under the plasma concentration-time curve (AUC) |
Measure: | Pharmacokinetics |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | The maximum observed plasma drug concentration after single dose administration (Cmax) |
Measure: | Pharmacokinetics |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | The time to reach maximum plasma concentration (Tmax) |
Measure: | Pharmacokinetics |
Time Frame: | 2 weeks (t1/2 will be assessed after the first two doses of IMCnyeso, an average of 2 weeks) |
Safety Issue: | |
Description: | The elimination half-life (t1/2) |
Measure: | Pharmacokinetics |
Time Frame: | up to 2 years |
Safety Issue: | |
Description: | The incidence of anti-IMCnyeso antibody formation |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Not yet recruiting |
Lead Sponsor: | Immunocore Ltd |
Trial Keywords
- Melanoma
- Lung Cancer
- Bladder Cancer
- Sarcoma
- IMCnyeso
- Immunotherapy
Last Updated